[New therapeutic strategies for retinoblastoma: non-systemic chemotherapy]. / Neue Therapiestrategien beim Retinoblastom: Nichtsystemische Chemotherapie.

ABSTRACT

Retinoblastoma is the most common primary intraocular malignancy worldwide. The known established standard therapies for bilateral disease, such as external beam radiation therapy or systemic chemotherapy often lead to a higher morbidity and increased risk of secondary malignancies, especially with radiation therapy. Therefore, new non-systemic chemotherapy strategies, such as the intra-arterial or intravitreal administration of melphalan are being revised with the aim of reducing systemic side effects.